Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma

Abstract

Introduction: The aim of this study is to evaluate whether the administration of renin-angiotensin system (RAS) inhibitors, angiotensin-I converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), is associated with treatment outcome in patients with esophageal squamous cell carcinoma. Materials and methods: A total of 141 esophageal squamous cell carcinoma patients receiving esophagectomy were identified, and were divided into two groups: an ACEI/ARB group (n=20), and a non-ACEI/ARB group (n=121). The effect of ACEIs or ARBs on cell proliferation and vascular endothelial growth factor (VEGF) secretion of esophageal squamous cell carcinoma cell lines, CE81T/VGH and TE2, were investigated by 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and Enzyme-linked immunosorbent assay (ELISA), respectively. Results: Use of ACEI/ARB (p=0.032), pathologic T stage (p<0.001), pathologic N stage (p=0.012), tumor stage (p=0.006), and tumor location (p=0.032) were significantly associated with superior overall survival. In multivariate comparison, use of ACEI/ARB (p=0.006), tumor stage (p=0.002), and tumor location (p=0.014) represented the independent prognosticators of superior overall survival. In cell lines, ACEIs/ARBs inhibit cell proliferation and VEGF secretion in a dose-dependent manner. Conclusions: ACEIs/ARBs administration is independently associated with superior overall survival in patients with esophageal squamous cell carcinoma receiving esophagectomy. Our data support further investigation of the role of RAS inhibitors as a potential therapy in esophageal squamous cell carcinoma.

Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study

“…Nevertheless, our results are consistent with findings of longer survival among gastro‐oesophageal cancer patients using renin‐angiotensin system blockade medications in two other studies based in Taiwan and Korea . However, each of these were substantially limited by poor generalisability (e.g.…”

Impact of renin‐angiotensin system blockade on clinical outcome in glioblastoma

“…Interestingly, the levels of VEGF secreted by tumour-associated macrophages in a melanoma model were strongly reduced in AT1R null mice, suggesting that the AT1R might also participate in inflammation-related tumour angiogenesis in vivo [13]. In line with these pre-clinical results, several retrospective studies have shown a better outcome in patients with various cancers (lung cancer, pancreatic cancer, gastric cancer, oesophageal carcinoma) when treated with Ang-II inhibitors [18][19][20][21]. It is shown here that treatment with Ang-II inhibitors is also associated with a better outcome in newly diagnosed GBM patients.…”

Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis

“…16 Chen et al indicated that administration of ACEIs/ARBs was independently associated with superior overall survival in patients with esophageal squamous cell carcinoma receiving oesophagectomy. 17 Our analysis has several limitations. First, all the included studies were observational investigations and cannot thus support any causality between the use of ARB and LC risk.…”